Medtronic plc MDT it is expected to release earnings results for the third quarter of fiscal 2024, before the opening bell on February 20, 2024.
Analysts expect the Dublin, Ireland-based company to report quarterly profit of $1.26 per share, down from profit of $1.3 per share a year ago. Medtronic is expected to report quarterly revenue of $7.95 billion, according to data from Benzinga Pro.
The company recently announced CE Mark (Conformité Européenne) approval for the MiniMed 780G System with Simplera Sync, a single-use, all-in-one continuous glucose monitor (CGM) that does not require a lancing device or tape.
Additionally, Medtronic announced that it has received FDA approval for its Percept RC deep brain stimulation (DBS) system.
Medtronic shares fell 0.4% to close at $84.42 on Friday.
Benzinga readers can access the latest analyst ratings at Analyst stock ratings page. Readers can sort by stock title, company name, analyst firm, rating change or other variables.
Let’s look at how Benzinga is more accurate analysts rated the company in the recent period.
- Fiduciary Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $84 to $87 on December 22, 2023. This analyst has an accuracy rate of 73%.
- Oppenheimer Analyst Steven Lichtman reiterated the Perform rating with a price target of $89 on August 23, 2023. This analyst has an accuracy rate of 72%.
- UBS Analyst Matthew Taylor maintained a Sell rating and raised the price target from $79 to $82 on August 23, 2023. This analyst has an accuracy rate of 68%.
- Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and raised the price target from $100 to $102 on August 23, 2023. This analyst has an accuracy rate of 73%.
- Stifel analyst Rick Wise maintained a Buy rating and raised the price target from $92 to $95 on August 23, 2023. This analyst has an accuracy rate of 76%.
Read this next: Top 5 industrial stocks that could fall this quarter